Last update 21 Dec 2024
ETBX-021
Last update 21 Dec 2024
Overview
Basic Info
Drug Type Shared antigen vaccine, Therapeutic vaccine |
Synonyms Ad5 [E1-, E2b-]-HER2/neu Vaccine, ETBX 021 |
Target |
Mechanism HER2 modulators(Receptor protein-tyrosine kinase erbB-2 modulators) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
10
Clinical Trials associated with ETBX-021NANT Colorectal Cancer (CRC) Vaccine: A Phase 1b/2 Trial of the NANT CRC Vaccine vs Regorafenib in Subjects With Metastatic CRC Who Have Been Previously Treated With Standard-of-Care Therapy
QUILT-3.088 NANT Pancreatic Cancer Vaccine: Phase II Randomized Trial of the NANT Pancreatic Cancer Vaccine vs. Standard-of-Care as First- Line Treatment for Patients With Metastatic Pancreatic Cancer
NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC
100 Clinical Results associated with ETBX-021
Login to view more data
100 Translational Medicine associated with ETBX-021
Login to view more data
100 Patents (Medical) associated with ETBX-021
Login to view more data
100 Deals associated with ETBX-021
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Pancreatic Cancer | Phase 2 | US | 01 Aug 2018 | |
| Colorectal Cancer | Phase 2 | US | 25 May 2018 | |
| Non-Small Cell Lung Cancer | Phase 2 | - | 01 Feb 2018 | |
| Ovarian Cancer | Phase 2 | - | 01 Dec 2017 | |
| Squamous Cell Carcinoma of Head and Neck | Phase 2 | - | 01 Dec 2017 | |
| Transitional Cell Carcinoma | Phase 2 | - | 01 Dec 2017 | |
| Locally Advanced Unresectable Breast Carcinoma | Phase 1 | US | 01 Dec 2016 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 1/2 | 2 | SBRT+Aldoxorubicin Hydrochloride+GI-6301+GI-4000+ETBX-061+Cetuximab+ETBX-051+Leucovorin+ETBX-011+5-Fluorouracil+ALT-803+ETBX-021+nab-paclitaxel+CYCLOPHOSPHAMIDE+Avelumab+haNK+GI-6207+Regorafenib+Oxaliplatin+Capecitabine (NANT Colorectal Cancer (CRC) Vaccine) | lcdydqueqz(jybrpesrte) = adnxmqtuzl ilobpmyvuj (qokqkuplsm, rupxlhwiid - vegrmalonm) View more | - | 11 Dec 2024 | ||
(Regorafenib) | ueguarbtfs(wpiexciyqw) = kwjyozqvfb jagmjytzbf (ssgkkbsedz, hpltpconoz - szethgpwyn) View more | ||||||
Phase 1/2 | 3 | Avelumab+Aldoxorubicin HCl+GI-6301+GI-4000+ETBX-061+ETBX-051+Leucovorin+ETBX-011+fluorouracil+ALT-803+ETBX-021+nab-paclitaxel+cyclophosphamide+haNK for infusion+GI-6207+bevacizumab+Oxaliplatin+Capecitabine | tsxccyxbgi(jwzoevykws) = kovmqdpewi aqhdeinbvq (udjlwljnbz, nultcsugmj - ixkpyivhni) View more | - | 27 Aug 2024 | ||
Phase 1/2 | 4 | ppuassssgn(fetwfcreeh) = vllahhfftk gkaqlaapna (vajdavxvdf, yaxobikxry - nrthvrlhga) View more | - | 05 Aug 2024 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free